TARS
Tarsus Pharmaceuticals, Inc.Company with tickers: TARS
CIK
1819790
CUSIP
87650L103
Shares Outstanding
43,023,959
Website
https://www.tarsusrx.com
13F Activity (30d)
2 filings
1 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $162,054,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Revenue (ASC 606) | $15,000,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | $22,351,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Operating Income | $-6,122,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Net Income | $-6,967,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| EPS (Basic) | $-0.16 | USD/shares | 2026-03-31 | 10-Q | 2026-05-06 |
| EPS (Diluted) | $-0.16 | USD/shares | 2026-03-31 | 10-Q | 2026-05-06 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Segment (USD)
| Component | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Reportable Segment | $25,816,000 | $17,447,000 | $182,953,000 | $451,360,000 |
By Product & Service (USD)
| Component | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|---|---|
| Product | — | — | $0 | $14,729,000 | $180,059,000 | $451,360,000 |
| License And Collaboration | — | — | — | $2,718,000 | $2,894,000 | $0 |
| Collaboration Revenue | $0 | $3,960,000 | — | — | — | — |
| License Fees And Collaboration | — | — | $25,816,000 | — | — | — |
| License And Service | $0 | $53,067,000 | — | — | — | — |